businesspress24.com - Medivation Announces Participation at Two Upcoming Investor Conferences
 

Medivation Announces Participation at Two Upcoming Investor Conferences

ID: 1040383

(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 09/23/11 -- Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following two investor conferences:

The JMP Securities Healthcare Conference on September 27 at 1:30pm Eastern Time at the St. Regis Hotel in New York City

The NewsMakers in the Biotech Industry Conference on October 21 at 9:30am Eastern Time at the Millennium Broadway Hotel in New York City

Dr. Hung will provide an overview of Medivation and its clinical development programs. A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at . A replay also will be available for 30 days following the live presentation.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at .



Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Investor Relations
(650) 218-6900




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Aeolus Pharmaceuticals Files Request for Orphan Drug Designation of AEOL 10150 for Mitigation, and/or Treatment of Delayed Effects of Acute Radiation Exposure of the Lung
Paladin Labs Announces Proposed Increased Offer to Acquire Afexa Life Sciences for $0.81 per Share
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 23.09.2011 - 14:00 Uhr
Sprache: Deutsch
News-ID 1040383
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SAN FRANCISCO, CA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 146 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Medivation Announces Participation at Two Upcoming Investor Conferences
"
steht unter der journalistisch-redaktionellen Verantwortung von

Medivation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Medivation



 

Who is online

All members: 10 568
Register today: 1
Register yesterday: 2
Members online: 0
Guests online: 98


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.